Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 3
1991 1
1992 1
1995 1
1999 1
2000 1
2003 1
2005 1
2009 1
2013 1
2018 1
2019 2
2020 2
2021 2
2022 1
2023 3
2024 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.
Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Gao S, Chen KN, Dooms C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodríguez-Abreu D, Chaft JE, Novello S, Yang J, Keller SM, Samkari A, Spicer JD; KEYNOTE-671 Investigators. Wakelee H, et al. N Engl J Med. 2023 Aug 10;389(6):491-503. doi: 10.1056/NEJMoa2302983. Epub 2023 Jun 3. N Engl J Med. 2023. PMID: 37272513 Free PMC article. Clinical Trial.
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC.
Zhou C, Solomon B, Loong HH, Park K, Pérol M, Arriola E, Novello S, Han B, Zhou J, Ardizzoni A, Mak MP, Santini FC, Elamin YY, Drilon A, Wolf J, Payakachat N, Uh MK, Rajakumar D, Han H, Puri T, Soldatenkova V, Lin AB, Lin BK, Goto K; LIBRETTO-431 Trial Investigators. Zhou C, et al. N Engl J Med. 2023 Nov 16;389(20):1839-1850. doi: 10.1056/NEJMoa2309457. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870973 Free PMC article. Clinical Trial.
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial.
Spicer JD, Garassino MC, Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Chen KN, Dooms C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodríguez-Abreu D, Chaft JE, Novello S, Yang J, Arunachalam A, Keller SM, Samkari A, Gao S; KEYNOTE-671 Investigators. Spicer JD, et al. Lancet. 2024 Sep 28;404(10459):1240-1252. doi: 10.1016/S0140-6736(24)01756-2. Epub 2024 Sep 14. Lancet. 2024. PMID: 39288781 Clinical Trial.
Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma-Protocol of the Immuno-MESODEC study.
Van den Bossche J, De Laere M, Deschepper K, Germonpré P, Valcke Y, Lamont J, Stein B, Van Camp K, Germonpré C, Nijs G, Roelant E, Anguille S, Lion E, Berneman Z. Van den Bossche J, et al. Among authors: deschepper k. PLoS One. 2024 Jul 15;19(7):e0307204. doi: 10.1371/journal.pone.0307204. eCollection 2024. PLoS One. 2024. PMID: 39008481 Free PMC article.
Postpartum scarcity-adversity inflicts sex-specific cerebellar adaptations and reward behaviors in adolescence.
Maulik M, Looschen K, Smith C, Johnson K, Carman AF, Nagisetty C, Corriveau K, Salisbury C, Deschepper K, Michels M, Henderson-Redmond AN, Morgan DJ, Mitra S. Maulik M, et al. Among authors: deschepper k. Pharmacol Biochem Behav. 2023 Oct;231:173620. doi: 10.1016/j.pbb.2023.173620. Epub 2023 Aug 23. Pharmacol Biochem Behav. 2023. PMID: 37625522 Free PMC article.
A prospective, multicenter, noninterventional study of decision factors in the first-line treatment of metastatic non-small cell lung cancer.
Sibille A, Bustin F, Carestia L, Catala G, Compère C, Cuppens K, Colinet B, Coulon S, De Brucker N, Decoster L, Decoster L, Demedts I, Derijcke S, Deschepper K, Galdermans D, Janssens A, Ocak S, Oyen C, Pat K, Pieters T, Pruniau V, Surmont V, Vandekeere S, Vansteenkiste J. Sibille A, et al. Among authors: deschepper k. Acta Oncol. 2022 Jun;61(6):773-776. doi: 10.1080/0284186X.2022.2063700. Epub 2022 May 15. Acta Oncol. 2022. PMID: 35574825 No abstract available.
The genomic landscape of nonsmall cell lung carcinoma in never smokers.
Boeckx B, Shahi RB, Smeets D, De Brakeleer S, Decoster L, Van Brussel T, Galdermans D, Vercauter P, Decoster L, Alexander P, Berchem G, Ocak S, Vuylsteke P, Deschepper K, Lambrechts M, Cappoen N, Teugels E, Lambrechts D, De Greve J. Boeckx B, et al. Among authors: deschepper k. Int J Cancer. 2020 Jun 1;146(11):3207-3218. doi: 10.1002/ijc.32797. Epub 2019 Dec 10. Int J Cancer. 2020. PMID: 31745979
Influence of cisplatin-use, age, performance status and duration of chemotherapy on symptom control in advanced non-small cell lung cancer: detailed symptom analysis of a randomised study comparing cisplatin-vindesine to gemcitabine.
Vansteenkiste J, Vandebroek J, Nackaerts K, Dooms C, Galdermans D, Bosquée L, Delobbe A, Deschepper K, Van Kerckhoven W, Vandeurzen K, Deman R, D'Odemont JP, Siemons L, Van den Brande P, Dams N; Leuven Lung Cancer Group. Vansteenkiste J, et al. Among authors: deschepper k. Lung Cancer. 2003 May;40(2):191-9. doi: 10.1016/s0169-5002(02)00515-9. Lung Cancer. 2003. PMID: 12711121 Review.
24 results